Phase 2 study of safety and efficacy of nimotuzumab in pediatric Patients with progressive diffuse intrinsic pontine glioma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Brain Stem Neoplasms
  • Glioma
  • Neoplasm Recurrence, Local

abstract

  • Modest activity of nimotuzumab in DIPG, which has been shown previously, was confirmed: A small subset of DIPG patients appeared to benefit from anti-EGFR antibody treatment.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4201068

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nou091

PubMed ID

  • 24847085

Additional Document Info

start page

  • 1554

end page

  • 9

volume

  • 16

number

  • 11